LEADER 02735nam  2200613 a 450 
001 9910141272203321
005 20200520144314.0
010   $a1-280-59148-X
010   $a9786613621313
010   $a1-118-26589-0
010   $a1-118-26675-7
010   $a1-118-26679-X
035   $a(CKB)2670000000175224
035   $a(EBL)832587
035   $a(OCoLC)787842613
035   $a(SSID)ssj0000639670
035   $a(PQKBManifestationID)11401942
035   $a(PQKBTitleCode)TC0000639670
035   $a(PQKBWorkID)10605127
035   $a(PQKB)10764483
035   $a(MiAaPQ)EBC832587
035   $a(Au-PeEL)EBL832587
035   $a(CaPaEBR)ebr10558697
035   $a(CaONFJC)MIL362131
035   $a(OCoLC)797824835
035   $a(PPN)17900171X
035   $a(EXLCZ)992670000000175224
100   $a20111004d2012      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aPharmaceutical lifecycle management$b[electronic resource] $emaking the most of each and every brand /$fTony Ellery, Neal Hansen
210   $aHoboken, N.J. $cJohn Wiley & Sons$dc2012
215   $a1 online resource (413 p.)
300   $aIncludes index.
311   $a0-470-48753-4 
327   $apt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management.
330   $a A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands  The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they
606   $aPharmaceutical industry$xEconomic aspects
606   $aDrug approval$xEconomic aspects
615  0$aPharmaceutical industry$xEconomic aspects.
615  0$aDrug approval$xEconomic aspects.
676   $a338.4/76153
700   $aEllery$b Tony$0918659
701   $aHansen$b Neal$0918660
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910141272203321
996   $aPharmaceutical lifecycle management$92060233
997   $aUNINA